Tasquinimod (TASQ)

On The Horizon – Tasquinimod – Immunotherapy & An Anti-Angiogenic Agent

In my commitment to report “On the Horizon” treatments for advanced prostate cancer today I will discuss an investigational treatment known as Tasquinimod. It is an experimental treatment that is both an immunotherapy and anti-angiogenic agent (designed to prevent the development of blood vesicles which would feed a tumor allowing its growth). In phase 2 clinical trials it has shown its ability to prolong progression-free survival (PFS) and also overall survival (OS) in certain men with metastatic castration-resistant prostate cancer (mCRPC). Researcher at Duke University reported that in more than 2 years men who participated in the randomized, placebo-controlled trial [...]

On The Horizon- Tasquinimo, A Potential New Therapy You Will Probably Be Hearing More About for Men With Advanced Prostate Cancer

According to an analysis led by the Duke Cancer Institute, tasquinimo, an investigational prostate cancer treatment slows disease progression and may also increase survival, especially among men whose cancer has spread to the bones. This study that was published on Nov. 19, 2013, in the journal Clinical Cancer Research, shows that long-term survival and safety for the investigational drug was positive and that tasquinimod might become a new candidate for treating advanced and recurrent prostate cancer, especially in men with bone metastasis. "While all subgroups in the clinical trial, a phase 2 trial, benefited from tasquinimod, those whose cancer metastasized [...]

On the Horizon – Many More Novel Drugs for the Treatment of Advanced Prostate Cancer

There have been many potential targets identified for the treatment of advanced prostate cancer. Many of these targets are being actively explored with clinical trials designed to test some inhibitors of the targets. Antisense oligonucleotides (OGX-011) targets clusterin, a chaperone protein and OGX-427 which targets heat-shock protein 27 are among the inhibitors being evaluated. OGX-011 was tested with docetaxel (chemotherapy) in a randomized phase II trial. The results of the trial reported better overall survival in the combination arm (median, 23.8 and 16.9 months, respectively).28 Two additional phase III trials are ongoing to confirm these results in combination with chemotherapy: [...]

Tasquinimod (TASQ)- A New Phase 3 Trial Shows Promise To Slow Disease Progression

Results from a recent international randomized phase II trial for the drug tasquinimod (TASQ), shows that TASQ is a potential therapy for men with advanced prostate cancer. The men who received TASQ on average went twice as long without disease progression as those who received only a placebo. […]